Day: February 13, 2026

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Feb. 13, 2026 (GLOBE NEWSWIRE) — Refined Energy Corp. (CSE: RUU | OTC: RRUUF | FRA: CWA0) (“Refined” or the “Company“) is pleased to announce that it has closed the previously announced non-brokered “charity flow-through” private placement (the “CFT Private Placement”) of units in the capital of the Company (“Units”). Pursuant to the CFT Private Placement, the Company issued 1,428,572 Units at a price of C$1.05 per Unit for gross proceeds of C$1,500,000.60. Each Unit consists of one “flow-through” common share in the capital of the Company (a “FT Share”) and one common share purchase warrant (“Warrant”), with each Warrant entitling the holder thereof to purchase one common share in the...

SÃO PAULO, Brazil, Feb. 13, 2026 (GLOBE NEWSWIRE) — Lavoro Limited (Nasdaq: LVRO, LVROW) (the “Company” or “Lavoro”) announced today that it has notified the Nasdaq Stock Market LLC (“Nasdaq”) of its decision to voluntarily delist its ordinary shares, par value $0.001 per share (the “Ordinary Shares”) and its warrants exercisable for one Ordinary Share at an exercise price of $11.50 (the “Warrants”) from the Nasdaq Global Market. Lavoro intends to file a Form 25 (Notification of Removal of Listing) with the SEC to remove its Ordinary Shares and Warrants from listing on the Nasdaq Global Market on or about February 24, 2026 and deregister such securities under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as a result, Lavoro expects that the last trading day of its Ordinary Shares and...

Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will host a webcast to review the topline results of the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), on Tuesday, February 17, 2026. Detailed data will be presented at the 49th Macula Society Annual Meeting between February 25 – 28, 2026. Click here to register for the virtual webcast, which will begin at 8:00 AM ET. The live and archived webcast can...

VANCOUVER, B.C., Feb. 13, 2026 (GLOBE NEWSWIRE) — A.I.S. Resources Limited (TSXV: AIS, OTC-Pink: AISSF) (“AIS” or the “Company”) is pleased to announce that its board of directors (the “Board”) has approved a shareholder rights plan (the “Rights Plan”). The adoption of the Rights Plan is intended to ensure, to the extent possible, that all shareholders of the Company are treated fairly in connection with any take-over bid for the Company’s shares (as defined in the Rights Plan) and to protect against acquisitions of control of the Company through purchases of shares that are exempt from applicable Canadian take-over bid rules, also referred to as “creeping” take-over bids. The Rights Plan is substantially similar to shareholder rights plans adopted by other Canadian issuers, and it was not adopted in response...

DUBLIN, Feb. 13, 2026 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 11, 2026 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a minimum bid price of $1.00 per share, based on the closing bid price of the Company’s American Depositary Shares (“ADSs”) for the last 30 consecutive business days. This notice has no immediate effect on the listing of the Company’s ADSs, which will continue to trade at this time on the Nasdaq Global Select Market under the symbol “TRIB.” In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180...

CALGARY, Alberta, Feb. 13, 2026 (GLOBE NEWSWIRE) — South Bow Corp. (TSX & NYSE: SOBO) (South Bow or the Company) and the Pipeline and Hazardous Materials Safety Administration (PHMSA) have received the independent third-party root cause analysis (RCA) of the incident that occurred at Milepost 171 (MP-171) of the Keystone Pipeline on April 8, 2025, near Fort Ransom, N.D. Root cause analysis findings According to the RCA, the characteristics of the MP-171 incident were unique. Both the pipe and welds conformed to industry standards for design, materials, and mechanical properties. Additionally, the pipe was transported in accordance with industry standards, and the pipeline was operating within its design pressure at the time of the incident. The RCA identified:The failure resulted from a fatigue crack that originated along...

CUPERTINO, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) — Ambow Education Holding Ltd. (“Ambow” or the “Company”) (NYSE American: AMBO), a global innovator of AI-powered phygital (physical + digital) solutions for education, conferencing and events, today announced that it has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 with the Securities and Exchange Commission (the “SEC”). The Annual Report on Form 10-K can be accessed on the Company’s investor relations website at https://www.ambow.com and the SEC’s website at https://www.sec.gov. Shareholders and ADS holders may request a hard copy of the Annual Report containing its audited consolidated financial statements, free of charge, at ir@ambow.com or by mail at Ambow Education Holding Ltd., 10080 N. Wolfe RD, Suite SW3-200, Cupertino, CA 95014, USA. About...

NORWALK, Ct, Feb. 13, 2026 (GLOBE NEWSWIRE) — HCM IV Acquisition Corp. (Nasdaq: HACQU) (the “Company”), a blank check company whose business purpose is to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, announced today the closing of its previously announced initial public offering of 28,750,000 units, including 3,750,000 units issued pursuant to the full exercise by the underwriter of its over-allotment option. The units were sold at a price of $10.00 per unit. The Company’s units began trading on February 12, 2026 on the Nasdaq Global Market under the symbol “HACQU”. Each unit consists of one Class A ordinary share and one-fourth of one redeemable warrant. Each whole warrant is exercisable to purchase one Class A ordinary...

Joshua HareJoshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, LongeveronMr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborations Corporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company’s on-going business development activitiesMIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology...